275 related articles for article (PubMed ID: 33101770)
1. Molecular drivers and cells of origin in pancreatic ductal adenocarcinoma and pancreatic neuroendocrine carcinoma.
Gao HL; Wang WQ; Yu XJ; Liu L
Exp Hematol Oncol; 2020; 9():28. PubMed ID: 33101770
[TBL] [Abstract][Full Text] [Related]
2. The Eighth Edition of the American Joint Committee on Cancer Distant Metastases Stage Classification for Metastatic Pancreatic Neuroendocrine Tumors Might Be Feasible for Metastatic Pancreatic Ductal Adenocarcinomas.
Wen J; Chen J; Liu D; Xu X; Fan M; Zhang Z
Neuroendocrinology; 2020; 110(5):364-376. PubMed ID: 31357196
[TBL] [Abstract][Full Text] [Related]
3. Pancreatic neuroendocrine carcinoma G3 may be heterogeneous and could be classified into two distinct groups.
Tanaka H; Hijioka S; Hosoda W; Ueno M; Kobayashi N; Ikeda M; Ito T; Kodama Y; Morizane C; Notohara K; Taguchi H; Kitano M; Komoto I; Tsuji A; Hashigo S; Kanno A; Miyabe K; Takagi T; Ishii H; Kojima Y; Yoshitomi H; Yanagimoto H; Furuse J; Mizuno N
Pancreatology; 2020 Oct; 20(7):1421-1427. PubMed ID: 32891532
[TBL] [Abstract][Full Text] [Related]
4. Transformation from non-small-cell lung cancer to small-cell lung cancer: molecular drivers and cells of origin.
Oser MG; Niederst MJ; Sequist LV; Engelman JA
Lancet Oncol; 2015 Apr; 16(4):e165-72. PubMed ID: 25846096
[TBL] [Abstract][Full Text] [Related]
5. Current update on imaging for pancreatic neuroendocrine neoplasms.
Segaran N; Devine C; Wang M; Ganeshan D
World J Clin Oncol; 2021 Oct; 12(10):897-911. PubMed ID: 34733612
[TBL] [Abstract][Full Text] [Related]
6. Surgical Treatment of Patients with Poorly Differentiated Pancreatic Neuroendocrine Carcinoma: An NCDB Analysis.
Kaslow SR; Vitiello GA; Prendergast K; Hani L; Cohen SM; Wolfgang C; Berman RS; Lee AY; Correa-Gallego C
Ann Surg Oncol; 2022 Jun; 29(6):3522-3531. PubMed ID: 35246811
[TBL] [Abstract][Full Text] [Related]
7. Differentiation of pancreatic neuroendocrine carcinoma from pancreatic ductal adenocarcinoma using magnetic resonance imaging: The value of contrast-enhanced and diffusion weighted imaging.
Guo C; Chen X; Wang Z; Xiao W; Wang Q; Sun K; Zhuge X
Oncotarget; 2017 Jun; 8(26):42962-42973. PubMed ID: 28487490
[TBL] [Abstract][Full Text] [Related]
8. Prognostic relevance of molecular subtypes and master regulators in pancreatic ductal adenocarcinoma.
Janky R; Binda MM; Allemeersch J; Van den Broeck A; Govaere O; Swinnen JV; Roskams T; Aerts S; Topal B
BMC Cancer; 2016 Aug; 16():632. PubMed ID: 27520560
[TBL] [Abstract][Full Text] [Related]
9. The Levels of Tumor Markers in Pancreatic Neuroendocrine Carcinoma and Their Values in Differentiation Between Pancreatic Neuroendocrine Carcinoma and Pancreatic Ductal Adenocarcinoma.
Zhuge X; Guo C; Chen Y; Feng L; Jia R; Zhao Y; Sun K; Wang Z; Chen X
Pancreas; 2018; 47(10):1290-1295. PubMed ID: 30308534
[TBL] [Abstract][Full Text] [Related]
10. Neoplastic Progression in Neuroendocrine Neoplasms of the Pancreas.
Luchini C; Scarpa A
Arch Pathol Lab Med; 2023 Mar; ():. PubMed ID: 36881771
[TBL] [Abstract][Full Text] [Related]
11. Cell Type of Pancreatic Ductal Adenocarcinoma Origin: Implications for Prognosis and Clinical Outcomes.
Patil S; Dou Y; Kopp JL
Visc Med; 2022 Feb; 38(1):4-10. PubMed ID: 35295896
[TBL] [Abstract][Full Text] [Related]
12. The differentiation of pancreatic neuroendocrine carcinoma from pancreatic ductal adenocarcinoma: the values of CT imaging features and texture analysis.
Guo C; Zhuge X; Wang Q; Xiao W; Wang Z; Wang Z; Feng Z; Chen X
Cancer Imaging; 2018 Oct; 18(1):37. PubMed ID: 30333055
[TBL] [Abstract][Full Text] [Related]
13. Integrated Genomic and Clinicopathologic Approach Distinguishes Pancreatic Grade 3 Neuroendocrine Tumor From Neuroendocrine Carcinoma and Identifies a Subset With Molecular Overlap.
Umetsu SE; Kakar S; Basturk O; Kim GE; Chatterjee D; Wen KW; Hale G; Shafizadeh N; Cho SJ; Whitman J; Gill RM; Jones KD; Navale P; Bergsland E; Klimstra D; Joseph NM
Mod Pathol; 2023 Mar; 36(3):100065. PubMed ID: 36788102
[TBL] [Abstract][Full Text] [Related]
14. Clinical and Genomic Characterization of Pancreatic Ductal Adenocarcinoma with Signet-Ring/Poorly Cohesive Cells.
Simbolo M; Silvestris N; Malleo G; Mafficini A; Maggino L; Cocomazzi A; Veghini L; Mombello A; Pezzini F; Sereni E; Martelli FM; Gkountakos A; Ciaparrone C; Piredda ML; Ingravallo G; Paolino G; Nappo F; Rapposelli IG; Frassinetti L; Saragoni L; Lonardi S; Pea A; Paiella S; Fassan M; Brunetti O; Cingarlini S; Salvia R; Milella M; Corbo V; Lawlor RT; Scarpa A; Luchini C
Mod Pathol; 2023 Sep; 36(9):100251. PubMed ID: 37355152
[TBL] [Abstract][Full Text] [Related]
15. Do Canine Pancreatic Neuroendocrine Neoplasms Resemble Human Pancreatic Neuroendocrine Tumours? A Comparative Morphological and Immunohistochemical Investigation.
de Vries C; Konukiewitz B; Weichert W; Klöppel G; Aupperle-Lellbach H; Steiger K
J Comp Pathol; 2020 Nov; 181():73-85. PubMed ID: 33288156
[TBL] [Abstract][Full Text] [Related]
16. Curation of the Pancreatic Ductal Adenocarcinoma Subset of the Cancer Genome Atlas Is Essential for Accurate Conclusions about Survival-Related Molecular Mechanisms.
Peran I; Madhavan S; Byers SW; McCoy MD
Clin Cancer Res; 2018 Aug; 24(16):3813-3819. PubMed ID: 29739787
[No Abstract] [Full Text] [Related]
17. MUC1-C dictates neuroendocrine lineage specification in pancreatic ductal adenocarcinomas.
Luan Z; Morimoto Y; Fushimi A; Yamashita N; Suo W; Bhattacharya A; Hagiwara M; Jin C; Kufe D
Carcinogenesis; 2022 Feb; 43(1):67-76. PubMed ID: 34657147
[TBL] [Abstract][Full Text] [Related]
18. DNA methylation reveals distinct cells of origin for pancreatic neuroendocrine carcinomas and pancreatic neuroendocrine tumors.
Simon T; Riemer P; Jarosch A; Detjen K; Di Domenico A; Bormann F; Menne A; Khouja S; Monjé N; Childs LH; Lenze D; Leser U; Rossner F; Morkel M; Blüthgen N; Pavel M; Horst D; Capper D; Marinoni I; Perren A; Mamlouk S; Sers C
Genome Med; 2022 Mar; 14(1):24. PubMed ID: 35227293
[TBL] [Abstract][Full Text] [Related]
19. Dual role of autotaxin as novel biomarker and therapeutic target in pancreatic neuroendocrine neoplasms.
Toyohara T; Yoshida M; Miyabe K; Hayashi K; Naitoh I; Kondo H; Hori Y; Kato A; Kachi K; Asano G; Sahashi H; Adachi A; Kuno K; Kito Y; Matsuo Y; Kataoka H
Cancer Sci; 2023 Dec; 114(12):4571-4582. PubMed ID: 37770812
[TBL] [Abstract][Full Text] [Related]
20. Genomic Heterogeneity of Pancreatic Ductal Adenocarcinoma and Its Clinical Impact.
Gutiérrez ML; Muñoz-Bellvís L; Orfao A
Cancers (Basel); 2021 Sep; 13(17):. PubMed ID: 34503261
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
